News from kodiak sciences inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

05:30 ET Kodiak Sciences Announces Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...

Feb 13, 2021, 08:28 ET Kodiak Sciences Announces 1-Year Durability, Efficacy and Safety Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion at the Angiogenesis, Exudation and Degeneration 2021 Annual Meeting

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...

Feb 02, 2021, 07:14 ET Kodiak Sciences Announces Upcoming Presentation of KSI-301 Phase 1b Clinical Study Data at Angiogenesis, Exudation, and Degeneration 2021 - Virtual Edition

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...

Jan 05, 2021, 08:02 ET Kodiak Sciences to Present at the J.P. Morgan Healthcare Conference

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...

Nov 20, 2020, 16:03 ET Kodiak Sciences Announces Closing of $645.0 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...

Nov 17, 2020, 21:02 ET Kodiak Sciences Announces Pricing of $560.9 Million Public Offering of Common Stock

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...

Nov 16, 2020, 16:01 ET Kodiak Sciences Announces Proposed Offering of Common Stock

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...

Nov 16, 2020, 06:53 ET Kodiak Sciences Completes Enrollment of DAZZLE Phase 2b/3 Pivotal Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...

Nov 12, 2020, 16:12 ET Kodiak Sciences to Present at Upcoming Conferences

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...

Nov 11, 2020, 23:27 ET Kodiak Sciences Announces Presentation of KSI-301 Phase 1b Clinical Study Data Focused on Diabetic Macular Edema at American Academy of Ophthalmology (AAO) 2020 Virtual Meeting

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...

Nov 09, 2020, 05:30 ET Kodiak Sciences Announces Third Quarter 2020 Financial Results and Recent Business Highlights

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...

Oct 05, 2020, 09:02 ET Kodiak Sciences Treats First Patients in Three Phase 3 Studies of KSI-301 - Two Studies in Diabetic Macular Edema and One Study in Macular Edema Due to Retinal Vein Occlusion

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...

Sep 02, 2020, 16:08 ET Kodiak Sciences to Present at Upcoming Conferences

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...

Aug 10, 2020, 05:30 ET Kodiak Sciences Announces Second Quarter 2020 Financial Results and Recent Business Highlights

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...

Jul 16, 2020, 16:38 ET Kodiak Sciences to Host R&D Webcast to Review Recent Data from the Ongoing Phase 1b Study of KSI-301 and Highlight KSI-301 Clinical Development Progress

Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence...

Jul 10, 2020, 16:00 ET Kodiak Sciences Announces New Longer-Term Safety, Efficacy and Durability Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion at the American Society of Retina Specialists (ASRS) 2020 Virtual Annual Meeting

Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence...

Jul 07, 2020, 08:38 ET Kodiak Sciences Announces Upcoming Presentation of KSI-301 Clinical Study Data at American Society of Retina Specialists (ASRS) 2020 Virtual Annual Meeting and R&D Webinar

Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence...

May 28, 2020, 08:22 ET Kodiak Sciences to Present at Upcoming Conferences

Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence...

May 11, 2020, 16:13 ET Kodiak Sciences to Present at the Bank of America Merrill Lynch Health Care Conference

Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company developing novel therapeutics to treat chronic, high-prevalence...

May 11, 2020, 05:30 ET Kodiak Sciences Announces First Quarter 2020 Financial Results and Recent Business Highlights

Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence...

May 08, 2020, 16:30 ET Kodiak Sciences to Host First Quarter 2020 Business Highlights Webcast on May 12, 2020

Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company developing novel therapeutics to treat chronic, high-prevalence...

Apr 02, 2020, 16:08 ET Kodiak Sciences Appoints Charles Bancroft to Board of Directors

Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company developing novel therapeutics to treat chronic, high-prevalence...

Mar 24, 2020, 08:51 ET "Kodiak" and "Kodiak Sciences" Trademarks Registered to Kodiak Sciences Inc. for Its Exclusive Use

Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence...

Mar 16, 2020, 05:30 ET Kodiak Sciences Announces Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights

Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence...

Feb 27, 2020, 06:00 ET Kodiak Sciences to Present at Upcoming Conferences

Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence...